26834 Secukinumab demonstrated sustained effectiveness in moderate-to-severe plaque psoriasis across weight categories: 36-month data from PURE

Authors :: Melinda Gooderham
Lenka Rihakova
Kim A. Papp
Adriana Leticia LopezTello Santillan
Mark Lomaga
Wei-Jing Loo
Jaggi Rao
Irina Turchin
Antonio Vieira
Vincent T. Ho
Hermenio C. Lima
Source :: Journal of the American Academy of Dermatology. 85:AB117
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Plaque psoriasis
Moderate to severe
Weight Categories
medicine.medical_specialty
business.industry
Medicine
Secukinumab
Dermatology
business

Tools